Vertex Pharmaceuticals Incorporated (VRTX) SVP Paul M. Silva Sells 4,213 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva sold 4,213 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $153.41, for a total value of $646,316.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up $3.12 during trading hours on Wednesday, hitting $157.26. The company had a trading volume of 1,901,860 shares, compared to its average volume of 2,090,000. The company has a market cap of $39,770.00, a P/E ratio of 80.65, a PEG ratio of 2.21 and a beta of 1.61. The company has a current ratio of 4.79, a quick ratio of 4.58 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $84.39 and a 52 week high of $174.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. The company had revenue of $651.63 million during the quarter, compared to the consensus estimate of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The firm’s revenue was up 42.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.35 EPS. research analysts predict that Vertex Pharmaceuticals Incorporated will post 1.63 EPS for the current year.

Vertex Pharmaceuticals declared that its Board of Directors has initiated a share buyback plan on Wednesday, January 31st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the pharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Several large investors have recently made changes to their positions in the stock. Verition Fund Management LLC grew its stake in shares of Vertex Pharmaceuticals by 8.4% during the 2nd quarter. Verition Fund Management LLC now owns 3,693 shares of the pharmaceutical company’s stock valued at $476,000 after acquiring an additional 287 shares during the period. Grandfield & Dodd LLC lifted its holdings in Vertex Pharmaceuticals by 5.9% in the 3rd quarter. Grandfield & Dodd LLC now owns 6,145 shares of the pharmaceutical company’s stock worth $934,000 after purchasing an additional 340 shares in the last quarter. First Republic Investment Management Inc. lifted its holdings in Vertex Pharmaceuticals by 2.8% in the 3rd quarter. First Republic Investment Management Inc. now owns 12,643 shares of the pharmaceutical company’s stock worth $1,922,000 after purchasing an additional 346 shares in the last quarter. Atria Investments LLC lifted its holdings in Vertex Pharmaceuticals by 7.9% in the 4th quarter. Atria Investments LLC now owns 4,765 shares of the pharmaceutical company’s stock worth $714,000 after purchasing an additional 350 shares in the last quarter. Finally, Advantus Capital Management Inc lifted its holdings in Vertex Pharmaceuticals by 1.5% in the 3rd quarter. Advantus Capital Management Inc now owns 25,555 shares of the pharmaceutical company’s stock worth $3,885,000 after purchasing an additional 369 shares in the last quarter. Institutional investors own 92.84% of the company’s stock.

Several equities research analysts recently commented on the company. JMP Securities reiterated an “outperform” rating and issued a $211.00 price objective (up from $200.00) on shares of Vertex Pharmaceuticals in a report on Tuesday. HC Wainwright reiterated a “hold” rating and issued a $103.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Credit Suisse Group lifted their price objective on Vertex Pharmaceuticals from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Finally, Jefferies Group reiterated a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $183.11.

TRADEMARK VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) SVP Paul M. Silva Sells 4,213 Shares” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/vertex-pharmaceuticals-incorporated-vrtx-svp-paul-m-silva-sells-4213-shares.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply